Cairo, November 2025 – In a historic move reflecting the private sector's commitment to supporting the national development agenda, Minapharm, a leading company in the development and manufacturing of biopharmaceuticals in Africa and the Middle East, announced the signing of a qualitative cooperation agreement with the global life science company, Bayer, aimed at localizing drug manufacturing in Egypt. This partnership aims to enhance access to essential medicines while establishing Egypt as a leading regional hub for manufacturing and exporting pharmaceutical products to the African continent.
The agreement sets a comprehensive framework for cooperation that includes a range of essential products in the fields of women's health, family planning, and neglected diseases. Specifically, the collaboration will encompass local production of seven essential medicines, representing a critical contribution to filling critical gaps in access to these treatments at the local level.
This partnership also represents a pivotal step towards enhancing the export of medicines dedicated to women's health to African markets, contributing to the continent's efforts to improve women's health and empower them to access sustainable and high-quality pharmaceutical care.
Dr. Wafiq Al-Bardisi, Chairman of Minapharm Pharmaceuticals and Managing Director, emphasized: “This partnership with Bayer embodies the mutual trust between the two parties and aligns with the state's directions for localizing drug manufacturing and enhancing global partnerships”. Further, Dr. Wafiq Al-Bardisi added, builds on Minapharm's extensive experience in technology transfer and international cooperation with major global companies, solidifying its position as a leading industrial platform capable of supporting national health policy objectives and expanding export reach to regional and African markets.
Hugo Hagen, Vice President & Head of Global Health Unit (GHU) at Bayer, emphasized "Egypt holds strategic importance within Bayer’s regional supply chain ecosystem. With its strong infrastructure and geographical advantages, Egypt is a key partner for Bayer in advancing access to high-quality medicines. Our collaboration with Minapharm reflects our commitment to supporting country’s efforts toward self-sufficiency in vital areas such as women’s health, while also localizing the production of essential medicines. This partnership contributes to a more sustainable and resilient healthcare system across the region."
This strategic partnership fully aligns with the national priorities of the Arab Republic of Egypt through three main axes: enhancing local pharmaceutical manufacturing and technology transfer, supporting women's health and family planning initiatives, and expanding Egyptian pharmaceutical export capabilities to African markets.
Both Minapharm and Bayer reaffirm their joint commitment to providing world-class medicines, supporting innovation and local manufacturing, contributing to building a healthier future for Egyptians and the entire African continent.